ArticleBMC cancer2025

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study.

Lihui Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.